CN100430384C - 制备4-(4-氨基苯基)-3-吗啉酮的方法 - Google Patents

制备4-(4-氨基苯基)-3-吗啉酮的方法 Download PDF

Info

Publication number
CN100430384C
CN100430384C CNB200480026537XA CN200480026537A CN100430384C CN 100430384 C CN100430384 C CN 100430384C CN B200480026537X A CNB200480026537X A CN B200480026537XA CN 200480026537 A CN200480026537 A CN 200480026537A CN 100430384 C CN100430384 C CN 100430384C
Authority
CN
China
Prior art keywords
morpholinone
aminophenyl
reaction
nitrophenyl
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB200480026537XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1852902A (zh
Inventor
C·托马斯
M·贝尔韦
A·施特劳布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of CN1852902A publication Critical patent/CN1852902A/zh
Application granted granted Critical
Publication of CN100430384C publication Critical patent/CN100430384C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB200480026537XA 2003-09-15 2004-09-09 制备4-(4-氨基苯基)-3-吗啉酮的方法 Expired - Lifetime CN100430384C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10342570A DE10342570A1 (de) 2003-09-15 2003-09-15 Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
DE10342570.5 2003-09-15

Publications (2)

Publication Number Publication Date
CN1852902A CN1852902A (zh) 2006-10-25
CN100430384C true CN100430384C (zh) 2008-11-05

Family

ID=34305779

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200480026537XA Expired - Lifetime CN100430384C (zh) 2003-09-15 2004-09-09 制备4-(4-氨基苯基)-3-吗啉酮的方法

Country Status (22)

Country Link
US (1) US7598378B2 (enExample)
EP (1) EP1664004B1 (enExample)
JP (1) JP4852419B2 (enExample)
KR (1) KR101148264B1 (enExample)
CN (1) CN100430384C (enExample)
AU (1) AU2004272255B2 (enExample)
BR (1) BRPI0414382B1 (enExample)
CA (1) CA2538906C (enExample)
CY (1) CY1116644T1 (enExample)
DE (1) DE10342570A1 (enExample)
DK (1) DK1664004T3 (enExample)
EG (1) EG26605A (enExample)
ES (1) ES2545072T3 (enExample)
HU (1) HUE025273T2 (enExample)
IL (1) IL174194A (enExample)
IN (1) IN2012DN00411A (enExample)
MX (1) MXPA06002883A (enExample)
PL (1) PL1664004T3 (enExample)
PT (1) PT1664004E (enExample)
SI (1) SI1664004T1 (enExample)
WO (1) WO2005026135A1 (enExample)
ZA (1) ZA200602093B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746288A (zh) * 2012-07-24 2012-10-24 常州制药厂有限公司 一种抗凝血药及其关键中间体的制备方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100898361B1 (ko) 2008-07-03 2009-05-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
WO2011080341A1 (en) 2010-01-04 2011-07-07 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
DE102010018299A1 (de) * 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
EP2613787A4 (en) * 2010-09-07 2014-04-16 Symed Labs Ltd PROCESSES FOR THE PREPARATION OF 4- {4- [5 (S) - (AMINOMETHYL) -2-OXO-1,3-OXAZOLIDIN-3-YL] PHENYL} MORPHOLIN-3-ONE
WO2012051692A1 (en) 2010-10-18 2012-04-26 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
EP2697209B1 (en) 2011-04-11 2015-09-23 Sandoz AG Method for the preparation of substituted oxazolidinones
EP2705028B1 (en) 2011-05-06 2019-08-21 Egis Gyógyszergyár Zrt. Process for the preparation of a rivaroxaban and intermediates formed in said process
WO2012156983A1 (en) * 2011-05-16 2012-11-22 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
CN102320988B (zh) * 2011-06-03 2014-04-09 中国科学院上海有机化学研究所 4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途
CN103288814B (zh) * 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法
IN2013MU01113A (enExample) 2013-03-25 2015-06-19 Glenmark Generics Ltd
KR20140127651A (ko) * 2013-04-25 2014-11-04 주식회사 종근당 4-(4-아미노페닐)-3-모폴리논의 신규한 제조 방법
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途
CA2929753A1 (en) 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils and use thereof
CN103709116B (zh) * 2013-12-10 2015-09-23 四川大学 一种4-(4-烷氧羰氨基)苯基-3-吗啉酮的制备方法
CN103755657B (zh) * 2013-12-25 2015-10-14 湖南方盛制药股份有限公司 一种利伐沙班中间体的制备方法
CN104974059B (zh) * 2014-04-14 2016-11-16 北大方正集团有限公司 一种利伐沙班中间体及其制备方法
CN105085370B (zh) * 2014-04-22 2017-04-12 北大方正集团有限公司 (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
EP3186246A1 (en) 2014-08-25 2017-07-05 Cipla Limited Process for the preparation of rivaroxaban
CN104478820B (zh) * 2014-12-22 2016-08-31 杭州瀚康生物医药科技有限公司 一种利伐沙班中间体的制备方法
CN104817548B (zh) * 2015-03-19 2017-12-01 郑州轻工业学院 一种对氢氧化锂、氢氧化钠、氢氧化钾可视化选择性识别的有机小分子
HU231119B1 (hu) 2018-01-12 2020-11-30 Richter Gedeon Nyrt. Eljárás 4-(4-aminofenil)morfolin-3-on előállítására
CN109651287A (zh) * 2019-01-18 2019-04-19 吕东 一种4-(4-氨基苯基)吗啉酮的制备方法
US12168167B2 (en) * 2023-01-11 2024-12-17 Kenneth W. Rittmann Golf club head cover device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047919A1 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung
WO2002064575A1 (de) * 2001-02-09 2002-08-22 Bayer Aktiengesellschaft Substituierte 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazoline und ihre verwendung als antikoagulant und antithrombotika
WO2003000256A1 (de) * 2001-06-20 2003-01-03 Bayer Healthcare Ag Kombinationstherapie substituierter oxazolidinone
WO2004101556A1 (en) * 2003-05-19 2004-11-25 Sanofi-Aventis Deutschland Gmbh INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
WO2004101553A1 (en) * 2003-05-19 2004-11-25 Sanofi-Aventis Deutschland Gmbh BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
JPH10503768A (ja) * 1994-08-02 1998-04-07 メルク シヤープ エンド ドーム リミテツド アゼチジン、ピロリジンおよびピペリジン誘導体
EP0912175A4 (en) * 1996-06-28 1999-09-08 Merck & Co Inc FIBRINOGENIC RECEPTOR ANTAGONISTS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047919A1 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung
WO2002064575A1 (de) * 2001-02-09 2002-08-22 Bayer Aktiengesellschaft Substituierte 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazoline und ihre verwendung als antikoagulant und antithrombotika
WO2003000256A1 (de) * 2001-06-20 2003-01-03 Bayer Healthcare Ag Kombinationstherapie substituierter oxazolidinone
WO2004101556A1 (en) * 2003-05-19 2004-11-25 Sanofi-Aventis Deutschland Gmbh INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
WO2004101553A1 (en) * 2003-05-19 2004-11-25 Sanofi-Aventis Deutschland Gmbh BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746288A (zh) * 2012-07-24 2012-10-24 常州制药厂有限公司 一种抗凝血药及其关键中间体的制备方法

Also Published As

Publication number Publication date
WO2005026135A1 (de) 2005-03-24
DK1664004T3 (en) 2015-09-07
BRPI0414382B1 (pt) 2014-01-28
IL174194A (en) 2010-11-30
KR20060070561A (ko) 2006-06-23
PL1664004T3 (pl) 2015-11-30
PT1664004E (pt) 2015-09-21
IN2012DN00411A (enExample) 2015-08-21
CN1852902A (zh) 2006-10-25
HUE025273T2 (en) 2016-02-29
MXPA06002883A (es) 2006-06-05
US7598378B2 (en) 2009-10-06
CA2538906C (en) 2013-04-23
IL174194A0 (en) 2006-08-01
EP1664004A1 (de) 2006-06-07
DE10342570A1 (de) 2005-04-14
US20070066611A1 (en) 2007-03-22
EP1664004B1 (de) 2015-06-24
EG26605A (en) 2014-03-23
KR101148264B1 (ko) 2012-05-21
ES2545072T3 (es) 2015-09-08
BRPI0414382A (pt) 2006-11-21
JP4852419B2 (ja) 2012-01-11
CY1116644T1 (el) 2017-03-15
CA2538906A1 (en) 2005-03-24
SI1664004T1 (sl) 2015-10-30
HK1098134A1 (zh) 2007-07-13
ZA200602093B (en) 2007-05-30
AU2004272255A1 (en) 2005-03-24
JP2007505821A (ja) 2007-03-15
AU2004272255B2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
CN100430384C (zh) 制备4-(4-氨基苯基)-3-吗啉酮的方法
JP6456143B2 (ja) カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
TWI309651B (en) Method for the manufacture of anagrelide
CN105017260B (zh) 一种西他列汀中间体三唑并吡嗪衍生物的制备方法
JP2002518388A (ja) モルホリン誘導体の化学合成
CA2010989A1 (fr) Derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JPS646192B2 (enExample)
HK1098134B (en) Method for the production of 4-(4-aminophenyl)-3-morpholinon
US3352877A (en) Process for preparing 5-halo-2-aminophenyl-3-aryl ketones
CN104926807A (zh) 一种利伐沙班相关物质“二胺”及其合成方法
CH635588A5 (fr) Procedes de preparation de thieno(2,3-c) et thieno(3,2-c)pyridines.
JPS6363658A (ja) 置換インドリノン誘導体の製造法
JPH05194485A (ja) 医薬化合物及びその製造方法
CN105294697B (zh) 2-氨基-5,8-二甲氧基[1,2,4]三唑并[1,5-c]嘧啶的合成方法
CN100395246C (zh) 用于制造叶酸拮抗剂及其中间体的方法
CN103626630B (zh) 利伐沙班中间体及其制备方法
CN106045931A (zh) 一种5‑苯基‑1‑（4‑甲氧基苯基）‑1h‑四氮唑的制备方法
CN117304101A (zh) 米他匹伐的制备方法
JPH11310558A (ja) ２―アミノ―４，５，３’，４’―テトラメトキシベンゾフェノンの製造方法
CN115490678A (zh) 一种高纯度利伐沙班的制备方法
CN102304125A (zh) 一种用于制备利奈唑胺的中间体
CN102010377A (zh) 高纯度白色2-羟基喹恶啉结晶制备方法
CH311979A (fr) Procédé de préparation d'un sel d'ammonium quaternaire.
CN105777609A (zh) 一种7-苯甲酰基-1,3-二氢吲哚-2-酮的制备方法
CZ2011518A3 (cs) Zpusob prípravy 4-(4-aminofenyl)morfolin-3-onu katalytickou hydrogenací ve vode

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098134

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098134

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG

Effective date: 20130322

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: BAYER PHARMACEUTICALS AG

Free format text: FORMER NAME: BAYER SCHERING PHARMA AG

CP01 Change in the name or title of a patent holder

Address after: Berlin

Patentee after: BAYER PHARMA AG

Address before: Berlin

Patentee before: Bayer Schering Pharma AG

TR01 Transfer of patent right

Effective date of registration: 20130322

Address after: German Monheim

Patentee after: BAYER INTELLECTUAL PROPERTY GmbH

Address before: Berlin

Patentee before: BAYER PHARMA AG

CP02 Change in the address of a patent holder

Address after: On the Rhine River, Germany

Patentee after: BAYER INTELLECTUAL PROPERTY GmbH

Address before: Germany

Patentee before: BAYER INTELLECTUAL PROPERTY GmbH

CP02 Change in the address of a patent holder
CX01 Expiry of patent term

Granted publication date: 20081105

CX01 Expiry of patent term